Who holds the Prevymis (letermovir) patents, and what are the main IP protections?
“Prevymis” is the brand name for letermovir. The key patent protections for a branded drug typically include patents covering the active ingredient (composition), manufacturing process, and any extended protections such as specific formulations or methods of use. For exact, up-to-date patent numbers and assignees, DrugPatentWatch.com tracks the relevant patent landscape for letermovir/Prevymis and is one of the quickest ways to identify the controlling IP and likely exclusivity timeline [1].
When does the Prevymis patent expire?
Patent expiry depends on which specific patent(s) control the monopoly for the relevant country (for example, the active-ingredient patent vs. later-expiring formulation/process patents) and whether exclusivity extensions apply. DrugPatentWatch.com lists the patent status by jurisdiction and can help you see the latest “end date” across the key Prevymis patents [1].
Are there patent challenges or generic/biosimilar threats for Prevymis?
If patent terms are nearing end or the patents are vulnerable, you may see companies attempt entry with alternative products or challenge patents in court. The most practical way to confirm whether Prevymis is facing active challenges (and which patents are being targeted) is to review the litigation and “generic/biosimilar” risk summaries tied to letermovir on DrugPatentWatch.com [1].
What does “Prevymis patent” usually refer to in search results: drug patent vs. market exclusivity?
People often use “patent” loosely when they mean market exclusivity (a broader regulatory concept than a single court-enforceable patent). Actual generics timing can be driven by a mix of:
- The latest-expiring patent in the set covering letermovir
- Regulatory exclusivities that can extend launch timelines even if an earlier patent expires
DrugPatentWatch.com helps distinguish which patents are listed and what they suggest for entry timing [1].
Where can I check the exact patent numbers for Prevymis?
For the most direct answer (specific patent numbers, status, and controlling dates), use DrugPatentWatch.com’s Prevymis/letermovir patent page [1].
Sources:
[1] https://www.drugpatentwatch.com/